drugset
Drugs / BioLexa
last change Sep 2022 re-read 9 days ago

BioLexa

Developed for
atopic eczema
Investigated by
Hoth Therapeutics, Inc. · Novotech (Australia) Pty Limited

Trials 1

today NCT04544943 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04544943 May 2021 → Sep 2022 atopic eczema Hoth Therapeutics, Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2017-06-20 Hoth Therapeutics, Inc. SPHERIX INC. ANNOUNCES DEFINITIVE TERMS REACHED TO ACQUIRE CONTROLLING INTEREST IN HOTH THERAPEUTICS, A BIOPHARMACEUTICAL COMPANY DEVELOPING ITS BIOLEXA PLATFORM TO TREAT SKIN ILLNESS SUCH AS ECZEMA. hoththerapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BioLexa “twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects” NCT04544943 ↗
1

NCT04544943 ↗
Route Topical “Route of Administration: Topical; Dosage Form: Topical lotion.” NCT04544943 ↗